Shipping Protection by Route

Buy 3 for $100 and Get Free Shipping


The Role of Vitamins in Glaucoma Care

By combining proven eye pressure-lowering treatments with potential neuroprotective strategies, patients can take a more comprehensive approach to preserving their vision.

     Nutritional supplements to treat glaucoma is gaining more evidence as a tool to fight against vision loss from this irreversible disease. Glaucoma is a degeneration of the optic nerve associated with elevate eye pressure. The primary approach to manage glaucoma is reduction of eye pressure through eye drops, laser procedures, and surgery. Lowering the eye pressure has been shown to slow down the disease progression, but it is known that vision loss continues even when the eye pressure is reduced to low levels. While reduction of eye pressure reduces the stress on the optic nerve, fortifying the optic nerve’s ability to withstand these stresses is an area of unmet potential for treatment. These interventions are referred to as neuroprotection. 

 

     One of the key challenges in glaucoma is oxidative stress, which damages retinal ganglion cells and contributes to nerve degeneration. Nicotinamide and pyruvate have shown potential in supporting cellular health and energy production within the optic nerve, helping to slow the progression of the disease.

Pyruvate and Nicotinamide Dietary Supplement

Supports Mitochondrial Health

Prevents Oxidative Stress

Enhances Cellular Energy Protection

Improves Resilience of Optic Nerve Cells

Purchase Here

Nicotinamide

     Nicotinamide plays a crucial role in cellular metabolism by boosting levels of nicotinamide adenine dinucleotide (NAD+), a molecule essential for mitochondrial function and nerve cell survival. By enhancing NAD+ levels, nicotinamide may improve the resilience of optic nerve cells, potentially slowing vision loss in glaucoma patients.

Pyruvate

     Pyruvate has been recognized for its role in energy metabolism and neuroprotection. Pyruvate acts as a metabolic fuel, helping to improve mitochondrial efficiency and reduce oxidative stress. Mitochondrial dysfunction has been recognized as a driver to optic nerve degeneration and pyruvate is a key metabolite that enhances cellular energy production to aid in reducing harmful byproducts that contribute to nerve degeneration.

Dietary Supplements Can Support Lowering Eye Pressure as the Gold Standard Treatment of Glaucoma

     Although vitamin supplements can provide valuable supportive benefits, they should not be viewed as a standalone treatment for glaucoma. While interventions to reduce intraocular pressure are key and indeed primary in reducing the stress on the optic nerve that drives vision loss, vitamin supplements can complement those efforts by augmenting the optic nerve’s ability to withstand the stresses of glaucoma. 

     While compounds like nicotinamide and pyruvate may help support optic nerve health, they should only be used under the guidance of a healthcare professional. Patients should consult their glaucoma specialists before adding any new supplements to their regimen to ensure safety, efficacy, and compatibility with their existing treatment plan. By combining proven eye pressure-lowering treatments with potential neuroprotective strategies, patients can take a more comprehensive approach to preserving their vision.

For further reading in the medical literature regarding nicotinamide and pyruvate, please see the references below.

  1. De Moraes CG, John SWM, Williams PA, et al. Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial. JAMA Ophthalmol. 2022;140(1):11-18. doi:10.1001/jamaophthalmol.2021.4576 
  2. Tribble JR, Otmani A, Sun S, et al. Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction. Redox Biol. 2021;43:101988. doi:10.1016/j.redox.2021.101988 
  3. Williams PA, Harder JM, Foxworth NE, et al. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science. 2017;355(6326):756-760. doi:10.1126/science.aal0092 
  4. Hui F, Tang J, Williams PA, et al. Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: a crossover randomized clinical trial. Clin Exp Ophthalmol. 2020;48(7):903-914. doi:10.1111/ceo.13818 
  5. Fahmideh F, Marchesi N, Barbieri A, Govoni S, Pascale A. Non-drug interventions in glaucoma: Putative roles for lifestyle, diet and nutritional supplements. Surv Ophthalmol. 2022 May-Jun;67(3):675-696. doi:10.1016/j.survophthal.2021.09.002 
  6. Kouassi Nzoughet J, Chao de la Barca JM, Guehlouz K, et al. Nicotinamide deficiency in primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2019;60(7):2509-2514. doi:10.1167/iovs.19-27099 
  7. Babighian S, Gattazzo I, Zanella MS, et al. Nicotinamide: Bright potential in glaucoma management. Biomedicines. 2024;12(8):1655. doi:10.3390/biomedicines12081655 
  8. Harder JM, Guymer C, Wood JPM, et al. Disturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or rapamycin. Proc Natl Acad Sci U S A. 2020;117(52):33619-33627. doi:10.1073/pnas.2014213117 
  9. Williams PA, Harder JM, John SWM. Glaucoma as a metabolic optic neuropathy: making the case for nicotinamide treatment in glaucoma. J Glaucoma. 2017;26(12):1161-1168. doi:10.1097/IJG.0000000000000767 
  10. Williams PA, Harder JM, Cardozo BH, Foxworth NE, John SWM. Nicotinamide treatment robustly protects from inherited mouse glaucoma. Commun Integr Biol. 2018;11(1):e1356956 
  11. Quah Qin Xian N, Wong FYK. Combined use of nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma. JAMA Ophthalmol. 2022;140(4):440. doi:10.1001/jamaophthalmol.2022.0155 
  12. Tasneem Zainab Khatib, Zac Wennberg Smith, Jeffrey Louis Goldberg. Tolerability and efficacy of open-label nicotinamide and pyruvate supplementation for primary open-angle glaucoma over 16 months. Invest Ophthalmol Vis Sci. 2024;65(7):669 
  13. Williams PA, Harder JM, Foxworth NE, Cardozo BH, Cochran KE, John SWM. Nicotinamide and WLDS act together to prevent neurodegeneration in glaucoma. Front Neurosci. 2017;11:232 
  14. Shukla A, Garg Cioffi GA, John SWM, Wang Q, Liebmann JM, et al. American Glaucoma Society-American Academy of Ophthalmology position statement on nicotinamide use for glaucoma neuroprotection. Ophthalmology Glaucoma.
  15. Gomes AP, Price NL, Ling AJ, et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624-1638. doi:10.1016/j.cell.2013.11.037 

Copyright © 2024. All Rights Reserved.

Home

Product

Contact Us

Title